- Kurapa
- Uchapupu
- Neuroblastoma
- Gomarara Rakasimba
- Uchapupu
- TILS
- Kurapa Masero eNK
- Myasthenia Gravis (MG)
- Acute Lymphoblastic Leukemia (B-ALL)
- Systemic Lupus Erythematosus (SLE)
- Chirwere cheAcute Lymphoblastic Leukemia (T-ALL)
- Non Hodgkin Lymphoma (NHL)
- Multiple Myeloma (MM)
- Kuparadzira Lymphom yeB-cell yakakura
- B-lymphocytic Leukemia
- Myeloma
CAR-T yeAcute B-cell Lymphoblastic Leukemia (B-ALL)
Pfupiso
B-ALL (Acute B-cell Lymphoblastic Leukemia) imhando yeleukemia inorwisa zvakanyanya, inonyanya kubata vana nevakuru vechidiki. Pasinei nekufambira mberi mukurapa kwemishonga yechinyakare, varwere vazhinji vanodzokera shure kana kuramba kurapwa. Kurapa kweCAR-T (Chimeric Antigen Receptor T-cell) kunomiririra kurapa kwezvirwere zvemuviri kwakaratidza kubudirira kukuru mukurapa B-ALL inodzokera shure kana isingadzoreki, zvichipa tariro kuvarwere vaimbova nesarudzo shoma dzekurapa.
Chii chinonzi CAR-T Therapy?
Kurapa kweCAR-T inzira yepamusoro uye yakagadzirwa nemunhu wese inosanganisira kugadzirisa maT-cell emurwere kuti aone uye arwise masero egomarara. Kune maB-ALL, masero eCAR-T akagadzirwa kuti arwise CD19 antigen, puroteni inowanzo kuwanikwa pamusoro pemasero eB-cell leukemia. Kana angodzoserwa mumuviri wemurwere, aya maT-cell akagadzirwa anotsvaga nekuparadza masero eleukemia, zvichikonzera kuregererwa kwenguva refu.
Mabhenefiti Akakosha ekurapa kweCAR-T paB-ALL
- Kushanda Kwakanyanya: Kurapa kweCAR-T kwakaratidza kubudirira kukuru mukurapa B-ALL inodzokera shure kana kuti isingarapiki, zvichipa mukana wepamusoro wekurerukirwa muvarwere vasina kupindura kurapwa kwechinyakare.
- Chiito Chakanangwa: Nekutarisa paCD19 antigen, kurapwa kweCAR-T kunonyanya kunanga nekuparadza masero eB-ALL, zvichideredza kukuvara kwematishu ane hutano.
- Kurapwa Kwakasiyana Nevamwe: Sezvo masero eCAR-T achitorwa kubva mudziviriro yemuviri yemurwere, kurapwa kwacho kwakagadzirirwa munhu mumwe chete, kuchiwedzera kushanda kwayo uye kunoderedza njodzi yekurambwa.
- Kuregererwa Kunogara: Muzviitiko zvakawanda, kurapwa kweCAR-T kwakaita kuti varwere vanzwe kurerukirwa kwenguva refu, zvichipa varwere mukana wekurarama kwenguva refu vasina kudzokazve kwenguva refu.
Maitiro Ekurapa
- Kuunganidzwa kwemasero eTDanho rekutanga rinosanganisira kuunganidza maT-cell kubva muropa remurwere kuburikidza nemaitiro anonzi leukapheresis.
- Masero eT einjiniya: Masero eT akaunganidzwa anogadziriswa majini murabhoritari kuti abudise chimeric antigen receptor (CAR) chaiyo kuCD19, zvichiwedzera kugona kwawo kunanga masero eB-ALL.
- Kuiswa kweCAR-T Cells: Mushure menguva pfupi yekukura kwemasero, masero eCAR-T akagadzirwa anodzoserwa mumuviri wemurwere kuburikidza nekuiswa mutsinga (IV).
- Kuongorora uye Kupora: Mushure mekunwa mushonga uyu, varwere vanotariswa zvakanyanya kuti vaone kana paine migumisiro yakaipa yakadai se cytokine release syndrome (CRS) uye neurotoxicity. Izvi zvinowanzo gadziriswa, uye ruzhinji rwevarwere vanopora kana paine nzira dzakakodzera.
Sei Uchifanira Kusarudza Kurapa kweCAR-T kweBIOOCUS paB-ALL?
- Tekinoroji Yemazuva AnoBIOOCUS inoshandisa tekinoroji yepamusoro-soro kuona kuti masero eCAR-T anogadzirwa zvakanaka uye kuti varwere vawane mhedzisiro yakanaka.
- Chikwata Chenyanzvi Chekurapa: Chikwata chedu chenyanzvi mukurapa ropa nezvirwere zvemuviri chakazvipira kupa rubatsiro rwemunhu oga uye kuwedzera kubudirira kwekurapa kwega kwega.
- Ruzivo Rwenyika Dzese: Tinopa CAR-T therapy kuvarwere vanobva kumativi ese enyika, neruzivo rwekubudirira kwekurapwa uye kurerukirwa kwenguva refu kwevarwere veB-ALL.
- Kutarisirwa KwakazaraKubva pakutanga kubvunzana kusvika pakuongororwa kwekutevera, BIOOCUS inopa rubatsiro rwakazara, ichivimbisa kuti varwere vanowana kurapwa kwakanakisisa padanho rega rega.
Uchapupu hweKliniki uye Mwero weKubudirira
Kuedzwa kwekiriniki munguva pfupi yapfuura uye data rechokwadi rakaratidza kuti kurapwa kweCAR-T kweB-ALL kunopa mhedzisiro yakanaka, kunyanya kune varwere vakadzokera kuchirwere kana kuti vasingadi kurapwa kwechinyakare. Kurapa uku kwagara kuchiratidza mwero wepamusoro wekuregererwa, varwere vazhinji vachiwana kuregererwa kwakakwana uye vachiramba vachirarama kwenguva refu.
KuBIOOCUS, takabudirira kurapa varwere vakawanda neB-ALL tichishandisa CAR-T therapy, uye mhedzisiro yacho yave yakanaka zvikuru. Kuti munzwisise zvakadzama nyaya dzekubudirira uye mhedzisiro chaiyo, ndapota tarisai zvidzidzo zvinotevera zvevarwere:
- Nyaya yeMurwere: B-ALL ine Njodzi Yakanyanya, Kuisirwa Bone Morrow paMwedzi Mipfumbamwe—Makore Maviri Mushure, Kutanga Kwakanaka
- Kubva Pakukundikana Kwekutanga Kwekuisirwa Chibereko Kusvika Pakupora Kwakazara: Rwendo rweMurwere Nekuisirwa Chibereko Chakanyanya chaLu Daopei
- Ruzivo rweChigadzirwa cheAcute Lymphoblastic Leukemia (B-ALL) uye Zvidzidzo zveNyaya
Nyaya idzi dzinoratidza kugona kwekurapa kweCAR-T kune varwere veB-ALL, zvichiratidza kwete chete kushanda kwekurapa asiwo kugona kwayo kupa varwere mukana wechipiri muhupenyu.
Ruzivo rweKliniki
Zviratidzo zveCD19+20CAR-T:Varwere vane B-cell non Hodgkin's lymphoma
| Mwedzi mumwe chete CR rate | Mutengo wePR wemwedzi mumwe chete | Mwedzi mumwe chete OR chiyero | CRS≥3 | CRES≥3 |
| 71.95% (59/82) | 25.6 (21/82) | 97.55（80/82） | 12.19% (10/82) | 0 |
Zviratidzo zveCD19+22CAR-T:Kurapa kwevarwere vane chirwere cheCD19 vane chirwere cheB-lymphocytic leukemia chinodzoka shure uye chisingadzoreki
| Mwedzi mumwe chete CR rate | Mutengo wePR wemwedzi mumwe chete | Mwedzi mumwe chete OR chiyero | CRS≥3 | CRES≥3 |
| 92.1% (35/38) | 7.9% (3/38) | 100% (38/38) | 15.79% (6/38) | 0 |
Zviratidzo zveBCMACAR-T:Kurapa kwe multiple myeloma inodzokera shure uye isingadzoreki
| Mwedzi mumwe chete CR rate | Mutengo wePR wemwedzi mumwe chete | Mwedzi mumwe chete OR chiyero | CRS≥3 | CRES≥3 |
| 72.41% (21/29) | 27.59% (8/29) | 100% (29/29) | 6.9% (2/29) | 0 |
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.